Trial Profile
Targeting Inflammation and Alloimmunity in Heart Transplant Recipients With Tocilizumab (RTB-004)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Methylprednisolone; Mycophenolate mofetil; Mycophenolate sodium; Prednisolone; Tacrolimus; Tacrolimus; Tacrolimus
- Indications Heart transplant rejection
- Focus Therapeutic Use
- 04 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 27 Mar 2023 Planned End Date changed from 1 Aug 2023 to 30 Apr 2025.
- 27 Mar 2023 Planned primary completion date changed from 1 Aug 2022 to 30 Apr 2025.